Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | EBP | Q15125 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2574419 | 0.92 | HTR1A (0.52) | HTR1ASLC6A4ABCB1EBPSIGMAR1 | |
| SCHEMBL1333914 | 0.92 | HTR1A (0.59) | HTR1ASLC6A4ABCB1 | |
| SCHEMBL2569813 | 0.91 | HTR1A (0.51) | HTR1ASLC6A4ABCB1EBPSIGMAR1 | |
| SCHEMBL1332119 | 0.91 | HTR1A (0.51) | HTR1ASLC6A4ABCB1EBPSIGMAR1 | |
| SCHEMBL1334517 | 0.90 | ABCB1 (0.60) | HTR1ASLC6A4ABCB1EBPSIGMAR1 | |
| SCHEMBL1332760 | 0.90 | HTR1A (0.50) | HTR1ASLC6A4ABCB1EBPSIGMAR1 | |
| SCHEMBL2573352 | 0.89 | HTR1A (0.49) | HTR1ASLC6A4ABCB1EBPSIGMAR1 | |
| SCHEMBL1333252 | 0.89 | ABCB1 (0.56) | HTR1ASLC6A4ABCB1EBPSIGMAR1 | |
| SCHEMBL1333775 | 0.88 | HTR1A (0.48) | HTR1ASLC6A4ABCB1EBPSIGMAR1 | |
| SCHEMBL2567216 | 0.88 | HTR1A (0.53) | HTR1ASLC6A4ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183374-B2 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20110281890-A1 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION | 2011-11-17 | — | — | US | disclosed |
| EP-1978959-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2011-11-09 | — | — | EP | disclosed |
| EP-1976525-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | AGY THERAPEUTICS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SUN CONNIE L | 2010-06-03 | — | — | US | disclosed |
| EP-1978959-A4 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2009-09-02 | — | — | EP | disclosed |
| EP-1978959-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES | M's Science Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008096189-A2 | PIPERIDINE AND PIPERAZINE DERIVATIVES | M'S SCIENCE CORPORATION (JP) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SIGMAR1, OPRM1, OPRD1 | HTR1A 23/4885SLC6A4 424/4885ABCB1 486/4885 |
| US-20110281890-A1 | Piperidine and piperazine derivatives | SIGMAR1, OPRM1, OPRD1 | HTR1A 49/4885SLC6A4 488/4885ABCB1 591/4885 |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | SIGMAR1, OPRM1, OPRD1 | HTR1A 50/4885SLC6A4 497/4885ABCB1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.